November 17, 2025

$VYUHPHARMA Highlights from the Week of November 10-17, 2025 ORGANON Organon and Henlius received FDA approval for their biosimilar, POHERDY, as the first interchangeable biosimilar to Roche's Perjeta, for use in HER2-positive breast cancer indications Pan amneal Amneal Pharmaceuticals received FDA approval for IOHEXOL injection, a generic radiographic contrast agent equivalent to Omnipaque, with launch expected in QI 2026 KURA ONCOLOGY The FDA granted full approval to Kura and Kyowa Kirin's oral therapy, KOMZIFTI (ziftomenib), for relapsed/refractory NPMI-mutated AML (FDA, Approval) (FDA, Approval) Pg 1/3 (FDA, Approval) All logos and trademarks remain the intellectual properties of their respective owners$

📢Highlights from the Week of 10 November – 17 November 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 10 November – 17 November 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of November 17th – 20th, 2025 💻

📢Highlights from the Week of 10 November – 17 November 2025 in the world of pharma and healthcare! 🗞️👀

The Pharma BI division of

Vyuhgenics Inc.

Connect with us